STANS, Switzerland,
April 5, 2021 /PRNewswire/ -- NLS
Pharmaceutics Ltd. (Nasdaq: NLSP, NLSPW) ("NLS" or the "Company"),
a Swiss clinical-stage pharmaceutical company focused on the
discovery and development of innovative therapies for patients with
rare and complex central nervous system disorders, announces the
appointment of Silvia Panigone, Ph.D., eMBA as Chief Operating
Officer. Dr. Panigone brings to NLS over 25 years of leadership
experience in the healthcare industry, founding and operating ADYA
Consulting, a boutique advisory firm that provides strategic
counseling, access to capital, and M&A advisory services to
companies in the life sciences sector, and serving in operational
and managerial roles in international pharmaceutical companies and
clinical research organizations.
"Silvia's outstanding experience in product development and
strategic leadership in the life sciences industry is a natural fit
for NLS as we pursue the development of Quilience® to treat
narcolepsy, and establish our strategy for business development and
advancement of our drug pipeline," said Alex Zwyer, Chief Executive Officer of NLS
Pharmaceutics. "Her proven ability to guide emerging
biotechnology and pharmaceutical companies from their early stages
of development through periods of significant growth will be
instrumental as we seek to drive our corporate initiatives and
build value within the Company. All of us at NLS extend a warm
welcome to Silvia."
"I am delighted to join the NLS team and to oversee the major
operational activities at the Company so that we can bring our
novel treatments for rare and complex CNS disorders to patients,"
said Dr. Panigone. "NLS is focused on the development of
therapeutics intended to satisfy unmet medical needs, and our lead
product, Quilience,® has the potential to become the first
treatment for narcolepsy that targets the orexin-2 receptor, the
root cause of the disorder. Given the importance of this product
candidate, our top priority is to obtain IND approval in the U.S.
and advance Quilience into the clinic as soon as possible."
Prior to joining NLS, Dr. Panigone was managing director of ADYA
Consulting Sagl, a Swiss investment boutique in the life sciences
sector operating globally and supporting companies in their
corporate strategy and fundraising. She also acted as interim
management in approximately one third of ADYA's biotech and pharma
clients, and has held several Board positions in private companies,
helping some realize M&A exits. Dr. Panigone combines a deep
understanding of both corporate finance and drug development
processes and execution. Prior to ADYA, she was former Managing
Director of Europe at I-Bankers
Direct LLC, an equity funding web platform, as well as Advisor for
I-Bankers Securities, Inc., a U.S. investment banking group with
over 140 lead and co-managed offerings. She previously served as
Fund Manager at BSI Healthcapital, a venture capital firm focused
on life sciences, and Head of Venture Investments in the Merchant
division of the Swiss-based bank, EFG International. Dr. Panigone's
extensive R&D experience includes serving in operational and
managerial positions at an international level in pharmaceutical
companies and CROs. In Bracco SpA, she led international programs
in both the preclinical and clinical stages of development with
teams of regulatory, intellectual property, CMC, preclinical and
clinical internal experts, external providers, and KOLs, overseeing
the development program as Sponsor. She was also Global Project
Manager at Quintiles Innovex Ltd., a leading global CRO, where she
was responsible for managing large clinical programs conducted in
the U.S., Europe and Asia. Previously, Dr. Panigone served as
Senior Director at XoVenture, a global network of Life Sciences
entrepreneurs and executives, Start-Up Coach for the Swiss
government (Innosuisse), Board Member of University of Milan, and was a member of the European
Network of Narcolepsy (EUNN). She earned a Molecular Biology degree
from the University of Milan, a
Ph.D. in Molecular Oncology at the National Cancer Institute and
Open University, London, and an
Executive MBA from SDA Bocconi School of Management, Milan.
About NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd. is a Swiss-based clinical-stage
biopharmaceutical company led by an experienced management team
with a track record of developing and repurposing product
candidates to treat rare and complex central nervous system
disorders. The Company's lead product candidate, Quilience® is a
proprietary controlled-release formulation of mazindol (mazindol
CR), and is being developed for the treatment of narcolepsy.
Mazindol is a triple monoamine reuptake inhibitor and partial
orexin receptor 2 agonist, which was used for many years to treat
patients diagnosed with narcolepsy in compassionate use programs.
NLS completed a phase 2 study in the U.S. evaluating mazindol CR in
adult subjects with ADHD. The study met all primary and secondary
endpoints and was well-tolerated. Quilience has received Orphan
Drug Designations both in the U.S. and in Europe for the
treatment of narcolepsy.
Safe Harbor Statement
This press release contains express or implied forward-looking
statements pursuant to U.S. Federal securities laws. For example,
NLS is using forward-looking statements when it discusses
Quilience® having the potential to become the first treatment for
narcolepsy that targets the orexin-2 receptor, the root cause of
the disorder, as well as when it discusses its strategy and
pipeline, initiatives and building value, as well as the potential
benefits and approval of Quilience® . These forward-looking
statements and their implications are based on the current
expectations of the management of NLS only, and are subject to a
number of factors and uncertainties that could cause actual results
to differ materially from those described in the forward-looking
statements. The following factors, among others, could cause actual
results to differ materially from those described in the
forward-looking statements: changes in technology and market
requirements; NLS may encounter delays or obstacles in launching
and/or successfully completing its clinical trials; NLS's products
may not be approved by regulatory agencies, NLS's technology may
not be validated as it progresses further and its methods may not
be accepted by the scientific community; NLS may be unable to
retain or attract key employees whose knowledge is essential to the
development of its products; unforeseen scientific difficulties may
develop with NLS's process; NLS's products may wind up being more
expensive than it anticipates; results in the laboratory may not
translate to equally good results in real clinical settings;
results of preclinical studies may not correlate with the results
of human clinical trials; NLS's patents may not be sufficient;
NLS's products may harm recipients; changes in legislation may
adversely impact NLS; inability to timely develop and introduce new
technologies, products and applications; loss of market share and
pressure on pricing resulting from competition, which could cause
the actual results or performance of NLS to differ materially from
those contemplated in such forward-looking statements. Except as
otherwise required by law, NLS undertakes no obligation to publicly
release any revisions to these forward-looking statements to
reflect events or circumstances after the date hereof or to reflect
the occurrence of unanticipated events. More detailed information
about the risks and uncertainties affecting NLS is contained under
the heading "Risk Factors" in NLS' final prospectus, dated
January 28, 2021, filed with the SEC,
which is available on the SEC's website, www.sec.gov.
Corporate Contact
Alex
Zwyer, CEO: +41 41 618 80 00
Investor Relations Contact
David Moskowitz: +1 202-280-0888
www.nlspharma.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/nls-pharmaceutics-appoints-silvia-panigone-phd-as-chief-operating-officer-301261618.html
SOURCE NLS Pharmaceutics Ltd.